Your browser doesn't support javascript.
loading
Development of a targeted behavioral treatment for smoking cessation among individuals with Chronic Obstructive Pulmonary Disease.
Mathew, Amanda R; Avery, Elizabeth F; Cox, Chelsea; Nwanah, Patrick; Kalhan, Ravi; Hitsman, Brian; Powell, Lynda H.
Afiliación
  • Mathew AR; Rush University Medical Center, Chicago, IL, USA. Amanda_mathew@rush.edu.
  • Avery EF; Rush University Medical Center, Chicago, IL, USA.
  • Cox C; University of Illinois at Chicago, Chicago, IL, USA.
  • Nwanah P; Rush University Medical Center, Chicago, IL, USA.
  • Kalhan R; Northwestern University Feinberg School of Medicine, 1700 W. Van Buren St, Ste. 470, 60612, Chicago, IL, USA.
  • Hitsman B; Northwestern University Feinberg School of Medicine, 1700 W. Van Buren St, Ste. 470, 60612, Chicago, IL, USA.
  • Powell LH; Rush University Medical Center, Chicago, IL, USA.
J Behav Med ; 46(6): 1010-1022, 2023 Dec.
Article en En | MEDLINE | ID: mdl-37148395
OBJECTIVE: Smoking cessation for individuals with Chronic Obstructive Pulmonary Disease (COPD) is medically critical, but smoking for coping motives is a common barrier. METHOD: In this evaluation of three treatment components (Mindfulness, Practice Quitting, and Countering Emotional Behaviors), we conducted two studies guided by the ORBIT model. Study 1 was a single-case design experiment (N = 18); Study 2 was a pilot feasibility study (N = 30). In both studies, participants were randomized to receive one of the three treatment modules. Study 1 examined implementation targets, changes in smoking for coping motives, and changes in smoking rate. Study 2 examined overall feasibility and participant-rated acceptability, and changes in smoking rate. RESULTS: Study 1: Treatment implementation targets were met by 3/5 Mindfulness participants, 2/4 Practice Quitting participants, and 0/6 Countering Emotional Behaviors participants. The Practice Quitting condition led to 100% of participants meeting the clinically significant threshold in smoking for coping motives. Incidence of quit attempts ranged from 0-50%, and smoking rate was reduced by 50% overall. Study 2: Recruitment and retention met feasibility targets, with 97% of participants completing all four treatment sessions. Participants reported high treatment satisfaction by qualitative responses and rating scales (M = 4.8/ 5.0). Incidence of quit attempts ranged from 25-58%, and smoking rate was reduced by 56% overall. CONCLUSIONS: These two small-N studies provide complementary findings on internal validity and implementation of the novel intervention. While Study 1 provided initial support for plausibility of clinically significant change, Study 2 provided data on key feasibility parameters. IMPLICATIONS: Smoking cessation for individuals with COPD is medically critical. We conducted an early-phase evaluation of a novel behavioral treatment focused on reducing smoking for coping motives. Results provided initial support for plausibility of clinically significant change and feasibility of the intervention.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Cese del Hábito de Fumar / Enfermedad Pulmonar Obstructiva Crónica Tipo de estudio: Clinical_trials / Prognostic_studies / Qualitative_research Límite: Humans Idioma: En Revista: J Behav Med Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Cese del Hábito de Fumar / Enfermedad Pulmonar Obstructiva Crónica Tipo de estudio: Clinical_trials / Prognostic_studies / Qualitative_research Límite: Humans Idioma: En Revista: J Behav Med Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos